The association of antiretroviral therapy (ART) with diabetes is inconsistent and varies widely across primary epidemiological studies. A comprehensive and more precise estimate of this association is fundamental to establishing a plausible causal link between ART and diabetes. We identified epidemiological studies that compared mean fasting plasma glucose (FPG) concentrations and proportions of diabetes and metabolic syndrome between HIV-infected patients naïve and exposed to ART. Mean difference in FPG concentrations and odds ratios of diabetes and metabolic syndrome were pooled using random-effects meta-analyses. Data on 20 178 participants from 41 observational studies were included in the meta-analyses. Mean FPG concentrations (Pooled mean difference: 4.66 mg/dL; 95% confidence interval [CI], 2.52 to 6.80; 24 studies) and the odds of diabetes (Pooled odds ratios: 3.85; 95% CI, 2.93 to 5.07; 10 studies) and metabolic syndrome (Pooled odds ratios: 1.45; 95% CI, 1.03 to 2.03; 18 studies) were significantly higher among ART-exposed patients, compared to their naïve counterparts. ART was also associated with significant increases in FPG levels in studies with mean ART duration ≥18 months (Pooled mean difference: 4.97 mg/dL; 95% CI, 3.10 to 6.84; 14 studies), but not in studies with mean ART duration <18 months (Pooled mean difference: 4.40 mg/dL, 95% CI, -0.59 to 9.38; 7 studies). ART may potentially be the single most consistent determinant of diabetes in people living with HIV worldwide. However, given the preponderance of cross-sectional studies in the meta-analysis, the association between ART and diabetes cannot be interpreted as cause and effect.
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| INTRODUCTION
In contrast to the declining trends in AIDS-specific deaths, the era of highly active antiretroviral therapy has been marked by an increase in non-AIDS-defining illnesses, notably cardio-metabolic events, among people living with HIV. 1 Antiretroviral therapy (ART) potentially underlies the pathogeneses of cardio-metabolic disorders, such as diabetes mellitus and metabolic syndrome, in most people living with HIV. 2, 3 While blood glucose levels tend to be slightly elevated in antiretroviral-naïve HIV-infected persons through mechanisms that remain unclear, evidence suggests that ART may exacerbate this effect by increasing insulin resistance and altering lipid metabolism. 2, 4 Expectedly, these mechanisms may potentially explain a link between ART and the metabolic syndrome, given that the latter is a constellation of cardio-metabolic abnormalities that may involve elevated fasting plasma glucose concentrations. 3 In addition, metabolic syndromewidely acknowledged as a risk factor for type 2 diabetes in the general population-has also been compared to the prediabetic state, the only distinction being the differences in diagnostic markers. 5, 6 Diabetes and metabolic syndrome are among the chief drivers of the global epidemic of cardiovascular disease. [7] [8] [9] [10] With approximately 36 million people currently living with HIV worldwide, 11 and a projected 18 million incident cases 12 by 2030, ART-associated diabetes and metabolic syndrome may portend substantial public health burden, potentially worsening the already-existing global burden of cardiovascular disease. However, the associations of ART exposure with diabetes mellitus and metabolic syndrome have not been consistent and vary widely in magnitude across primary epidemiological studies, with certain studies reporting significant direct associations, [13] [14] [15] [16] and other studies reporting no significant effects. [17] [18] [19] [20] Therefore, we aimed to obtain comprehensive and more precise estimates of the magnitudes of these associations. We also sought to investigate study-level factors that may influence the associations of ART with diabetes and metabolic syndrome in people living with HIV worldwide. Assessing these associations will provide a comprehensive evidence-base for investigating plausible causal links between ART and these cardio-metabolic disorders.
| MATERIALS AND METHODS
The study background, rationale, and methods were specified in advance and documented in a study protocol registered in the PROS-PERO database (CRD42014008855).
| Study selection
CUN, AMS, and OAU independently screened potentially eligible studies by their titles, abstracts, and full texts, and any disparities were resolved following discussions with the other investigators. We selected studies that compared mean fasting plasma glucose concentrations and prevalence estimates of diabetes and metabolic syndrome between ART-exposed and ART-naïve HIV-infected adults. Other criteria for study selection are summarized in Table 1 .
| Search strategy
We searched PubMed, EMBASE, and the World Health Organization (WHO) International Clinical Trials Registry Platform for all relevant articles published to date. The search was conducted using medical subject heading (MeSH) terms and keywords: blood glucose*/, diabetes mellitus*/, metabolic syndrome X*/, highly active antiretroviral therapy*/, antiretroviral therapy*/, antiretroviral-naïve.mp/, HAARTnaïve.mp/, HIV */. The electronic search was limited subsequently to studies of humans (see Appendices S1 and S2). We also scanned the bibliographies of relevant articles identified by the search.
| Data extraction
CUN, AMS, and OAU independently extracted data from each study using a piloted form, and any discrepancies were also resolved by consensus with the other investigators. Data on the following study-level characteristics were extracted: article citation, country of origin, country income group, geographical region, study design, sample size, mean age, proportion of females, proportion of current smokers and drinkers, number of ART-exposed and ART-naïve patients, mean CD4 count, mean duration of ART, proportion of patients on protease inhibitors, mean concentrations of fasting plasma glucose in ART-exposed and ART-naïve patients, and the proportions of diabetes and metabolic syndrome in ART-exposed and ART-naïve patients. Country income groups were defined according to World Bank development indicators. 21 Diabetes mellitus was defined as a fasting plasma glucose concentration ≥ 126 mg/dL (7 mmol/L) or a 2-hour postprandial blood glucose level ≥ 200 mg/dL (11.1 mmol/L). 22 Metabolic syndrome was defined as the presence of central obesity (waist circumference ≥ 94 cm for men and ≥80 cm for women) with any 2 of the following 4 criteria: serum triglyceride levels ≥150 mg/dL (or lipid lowering treatment); serum high density lipoprotein levels <40 mg/dL in males and <50 mg/dL in females (or specific treatment for this condition); blood pressure ≥ 130/85 mmHg (or antihypertensive treatment); fasting plasma glucose levels ≥100 mg/ dL (or previously diagnosed type 2 diabetes mellitus). 23 
| Risk of bias assessment
The methodological quality of each study was assessed using a domain-based checklist adapted from the Cochrane risk of bias tool for nonrandomized studies 24 (Table 2) . We investigated 5 potential sources of bias, including the selection of participants (selection bias), assessment of the exposure (information bias), assessment of the outcomes (information bias), adjustment for potential confounders, and loss to follow-up of patients (attrition bias).
| Statistical analysis
We pooled the weighted mean differences (MD) in fasting plasma glucose concentrations and the odds ratios (OR) of diabetes and metabolic syndrome in each study using the Dersimonian-Laird randomeffects model, which is appropriate to account for heterogeneity across the included studies. 25 The ORs of diabetes and metabolic syndrome were computed from their proportions in ART-exposed and ART-naïve patients. Heterogeneity across the included studies was measured using the I-squared statistic (I 2 ) for which a value between 75% and 100% indicated considerable heterogeneity. 26 Chi-square tests for heterogeneity were also performed to determine the statistical significance of heterogeneity at 5% level. We investigated publication bias in each meta-analysis using funnel plots and performed leaveone-study-out sensitivity analyses to ascertain the stability of the pooled effect estimates, which entailed omitting one study at a time while computing the meta-analyses. Random-effects subgroup and meta-regression analyses were performed on all study-level baseline characteristics to identify factors that may potentially modify the pooled associations, as well as possible sources of any observed heterogeneity across studies included in the meta-analyses. 27 The sub- Low risk:
• Participants are sampled randomly
• Similar recruitment strategies for ART-exposed and naïve participants
• Sample size was justified High risk:
• Participants are not selected randomly
• ART-exposed and naïve participants recruited differently
• Sample size was not justified
Unclear risk:
• Sampling strategy was not described
• Sample size was not calculated
Assessment of exposure (information bias)
Low risk:
• Well-defined exposure criterion
High risk:
• Exposure criterion not well defined, eg, studies may define ART exposure based on treatment duration of at least 1 mo, which misclassifies certain ART-exposed patients as ART-naïve
• Exposure criterion not stated
Assessment of outcomes (information bias)
• Blood glucose levels and diabetes risk are assessed similarly between ART-exposed and ART-naïve participants
• Blood glucose levels and diabetes risk are assessed using validated methods
High risk:
• Blood glucose levels and diabetes risk are assessed differently between ART-exposed and ART-naïve participants
• Blood glucose levels and diabetes risk are not measured using validated methods Unclear risk:
• Methods for assessing blood glucose levels and diabetes risk are not clearly described
Adjustment for confounding
• At least one major confounder is controlled High risk:
• No attempt at adjusting for confounders Follow-up of participants-for cohort studies (attrition bias)
• Loss to follow-up is less than 20%
• Loss to follow-up is 20% or more
Adapted after the Cochrane risk of bias tool for nonrandomized studies.
3 | RESULTS
| Study selection and characteristics
The study selection process is shown in Figure 1 . From 602 records identified through electronic database searching, 19 records from cross-references, and 28 417 records from the WHO International Clinical Trials Registry Platform, we excluded 560 abstracts and 11 duplicate records. Of 50 remaining full texts assessed for eligibility, 9 articles were withdrawn, leaving 41 studies that were deemed eligible for inclusion in the meta-analyses. [13] [14] [15] [16] [17] [18] [19] [20] In total, there were 20 178 participants, with approximately twice as many ART-exposed as there were ARTnaïve patients. The average age of the total study population was 42 years, and women accounted for 40%. Most studies were conducted in low-and middle-income countries, including Brazil, 19, 40, 41, 59 Camer- South Africa, 17, 31 Sri Lanka, 61 Thailand, 14 and Zambia. 46 However, the studies conducted in high-income countries were generally larger in size, comprising more than half of the total study population. Table 3 summarizes other characteristics of the included studies.
| Risk of bias within included studies
Selection bias was low in only 10 studies (24%); information bias with respect to assessment of the exposure was low in all 41 studies, but unclear or high with respect to outcomes assessment in 7 studies (83%); 34 studies (83%) adjusted for at least one important confounder; and loss to follow-up was less than 20% in 8 out of 10 included cohort studies (Figure 2 ). Figure 3 displays the meta-analysis of the association between ART and fasting plasma glucose concentrations. Mean fasting plasma glucose levels were compared between ART-exposed and ART-naïve patients in 24 studies, 12 of which reported significantly higher mean concentrations in ART-exposed patients.* Overall, mean fasting plasma glucose levels remained significantly higher in ART-exposed patients, compared to their naïve counterparts (Pooled MD: 4.66 mg/dL; 95% CI, 2.52 to 6.80; P < .001; 5069 participants). Heterogeneity across the included studies was considerable (I 2 = 81.2%) and statistically significant (P < .001). Analysis of publication bias revealed a symmetrical funnel plot ( Figure S1 ), and the pooled estimate did not change as to alter the interpretation of the association following serial exclusion of the included studies (Table 4) . .839
| Pooled association of ART with blood glucose concentration
increased blood glucose concentrations. However, in comparison to the numbers of participants in studies with mean BMI < 25 kg/m 2 (n = 3446) and studies with fewer smokers than nonsmokers (n = 2,843), the numbers of participants in studies with mean BMI ≥ 25 kg/m 2 (n = 625) and studies with more smokers than nonsmokers (n = 413) may have been too small to detect a statistically significant association between ART and blood glucose levels.
| Pooled association of ART with diabetes mellitus
As shown in Figure 4 , prevalence estimates of diabetes were compared between ART-exposed and ART-naïve patients in 10 studies, 5 of which revealed significantly higher odds of having diabetes in the ART-exposed group. 13, 14, 47, 54, 56 Among 7946 participants with reported diabetes status in the ART-exposed groups, 519 (6.5%) had diabetes, as opposed to 63 of 3379 (1.9%) in the ART-naïve groups.
Overall, the odds of having diabetes mellitus were approximately 4 times higher in ART-exposed patients, compared to their naïve counterparts (Pooled OR: 3.85; 95% CI, 2.93 to 5.07; P < .001; 11 328 participants). Studies included in the meta-analysis were not heterogeneous (I 2 = 0%). Analysis of publication bias revealed the absence of small-study effects as indicated by the absence of funnel plot asymmetry (see Figure S2) , and sensitivity analysis showed no change in the pooled estimate that would alter the interpretation of the overall association of ART with increased odds of diabetes.
( Table 4 ).
There were no significant differences between subgroup estimates of the pooled association between ART exposure and diabetes.
Nonetheless, in contrast to studies with less than 200 participants (Pooled OR: 1.79; 95% CI, 0.49 to 6.57; 3 studies), studies with more than 200 participants were likely to report a significant association (Pooled OR: 4.06; 95% CI, 3.06 to 5.38; 7 studies) ( Table 5 ).
| Pooled association of ART with metabolic syndrome
Prevalence estimates of metabolic syndrome were compared between ART-exposed and ART-naïve patients in 18 studies. † Among 5548 ART-exposed patients with reported metabolic syndrome status, 1048 (18.9%) were examined with metabolic syndrome, compared to 214 (14.2%) of 1506 patients in the ART-naïve group. In addition, the odds of being diagnosed with metabolic syndrome were significantly higher among ART-exposed patients, compared to ART-naïve patients (Pooled OR: 1.45; 95% CI, 1.03 to 2.03; P = .037; 7052 participants) ( Figure 5 ). Heterogeneity across the included studies was substantial (I 2 = 69.4%) and statistically significant (P < .001). Funnel plot was symmetrical ( Figure S3 ) and sensitivity analysis revealed no significant change in the pooled effect estimate following the sequential exclusion of studies from the meta-analysis (Table 4) . Subgroup and meta-regression analyses also revealed no significant differences between subgroup estimates of the pooled association between ART exposure and metabolic syndrome. Nonetheless, the analyses revealed Abbreviations: -, insufficient number of observations to perform analysis; ART, antiretroviral therapy; CD4, cluster of differentiation 4; MD, mean difference; N, number of studies; OR, odds ratio; PI, protease inhibitor.
qualitative differences in the pooled association between studies of patients who were at least 40 years of age (Pooled OR 2.34; 95% CI, 1.22 to 4.49; 7 studies) and those who were younger (Pooled OR:
1.14; 95% CI, 0.67 to 1.95; 8 studies); studies with more women than men (Pooled OR: 1.66; 95% CI, 1.28 to 2.14; 6 studies) and fewer women than men (Pooled OR: 1.49; 95% CI, 0.81 to 2.72; 7 studies);
and studies of patients from low/middle-income countries (Pooled OR: 1.61; 95% CI, 1.26 to 2.04; 10 studies) and those from highincome settings (Pooled OR: 1.27; 95% CI, 0.63 to 2.53; 8 studies) (Table 5 ).
| DISCUSSION
We present the first pooled analyses estimating the associations of Regarding ART duration, the observed association of ART exposure with increasing blood glucose levels in HIV-infected patients on ART for longer than 18 months but not in patients with shorter ART durations may suggest a plausible dose-response relationship between ART exposure and blood glucose levels. While our interpretation of this interaction somewhat contradicts previous studies reporting a lack of association between ART duration and fasting blood glucose concentrations, 30, 42 we cannot rule out the possibility that these 2 rather small-sized studies may not have been adequately powered to detect a significant association.
The observed associations of ART with increased odds of metabolic syndrome in HIV-infected patients above 40 years of age and in studies with more women than men, but not in younger patients or studies with fewer women than men, are broadly consistent with older age and female sex as risk factors for cardio-metabolic disorders in HIV-infected persons exposed to ART. 4, 65 In addition, the moderating given that the global prevalence of HIV and its untoward effects are driven by rates in low-and middle-income countries. 11 Thirdly, we acknowledge that the lack of data on glycated haemoglobin (HbA1c) levels is an important limitation of our study, especially with HbA1c now considered to be a better predictor of long-term diabetes risk than fasting plasma glucose concentrations in the general population. 70 Furthermore, most of the included studies were assessed to have a high risk of selection bias. However, subgroup and meta-regression analyses revealed no significant differences in the pooled estimates between studies with high/unclear and low risks of selection bias (see Table 5 ). The pooled estimates were not affected by selection bias.
Some of the unexplained heterogeneity across the included studies may have been driven by individual-level differences, such as differences in blood glucose concentrations prior to commencing ART, varying histories of antidiabetic treatment, potential variations in the pharmacodynamic interactions between antiretroviral drugs and oral hypoglycaemic agents, 71 and individual differences in lifestyle behaviours, such as alcohol abuse. However, individual-level differences
were not examined in the meta-analyses.
We could not examine the impact of certain lifestyle factors (such as smoking and alcohol use) and HIV-related characteristics (such as ART regimen, CD4 count, and HIV infection duration) on the associations of ART with diabetes mellitus and metabolic syndrome, given the insufficient number of studies required to perform these analyses. 26 We did not examine the impact of ART on gestational diabetes mellitus (GDM), given the dearth of evidence on this subject. Available data suggest that GDM prevalence estimates are statistically comparable between HIV-infected and HIV-non-infected pregnant mothers. 72 Similarly, the American Diabetes Association 2016 guidelines have not recommended different GDM screening protocols for HIV-infected and HIV-non-infected pregnant mothers. 73 Lastly, with only 2 cohort studies in which the association between ART and diabetes mellitus were examined, 17, 47 it was impossible to distinguish ART-associated diabetes from diabetes developed prior to the commencement of ART. 4 In spite of the above limitations, the timeliness of our study in filling an important gap by providing the most comprehensive and precise estimates quantifying the associations of ART with diabetes and metabolic syndrome in people living with HIV is noteworthy. Other important strengths of our study include novel findings of moderators of the associations of ART on diabetes and metabolic syndrome; rigorous search strategies and methodological assessments that were conducted by independent investigators; absence of small-study effects;
and stability of the pooled estimates as confirmed by sensitivity analyses.
In conclusion, while the findings preclude a cause and effect inter- 
